Risks
4 risks
Risk Intelligence
Atali plant stabilization delays
View Risks →Aarti Pharmalabs Limited — Q3 FY26
Aarti Pharmalabs reported Q3 FY26 revenue of ₹5,425 crore, up 15% YoY, but EBITDA fell to ₹103 crore (down 10% YoY) and PAT dropped to ₹44 crore (down 41% YoY), reflecting margin compression.
bearish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Aarti Pharmalabs reported Q3 FY26 revenue of ₹5,425 crore, up 15% YoY, but EBITDA fell to ₹103 crore (down 10% YoY) and PAT dropped to ₹44 crore (down 41% YoY), reflecting margin compression. The decline was driven by startup hiccups at the Atali plant, softness in API/intermediate business, and delayed CDMO project deliveries. Management revised FY26 EBITDA guidance to flat/marginal growth, citing these headwinds. Positives include a strong CDMO pipeline (40 commercial projects), Zanthin capacity expansion (targeting 9,600 MT by Q1 FY27), and potential pricing tailwinds from China's rebate withdrawal. However, near-term risks remain: Atali stabilization may slip, API pricing pressure persists, and CDMO revenue concentration on a few molecules. The stock may remain range-bound until execution improves.
आरती फार्मालैब्स ने तीसरी तिमाही में 5,425 करोड़ रुपये की कमाई की, जो पिछले साल से 15% ज्यादा है। लेकिन मुनाफा कम हुआ - कंपनी की कमाई और खर्च का अंतर (EBITDA) 103 करोड़ रुपये रहा (10% कम) और शुद्ध मुनाफा (PAT) 44 करोड़ रुपये (41% कम) हो गया। इसकी वजह है अटाली प्लांट में शुरुआती दिक्कतें, दवाओं के कच्चे माल (API) के कारोबार में सुस्ती, और कुछ CDMO प्रोजेक्ट्स में देरी। कंपनी ने इस साल के मुनाफे का अनुमान घटा दिया है। अच्छी बात यह है कि CDMO में 40 नए प्रोजेक्ट हैं और ज़ैंथिन उत्पादन बढ़ाने की योजना है। लेकिन नज़दीकी जोखिम भी हैं - अटाली प्लांट को स्थिर होने में समय लग सकता है और API की कीमतों पर दबाव बना रहेगा। शेयर की कीमत तब तक स्थिर रह सकती है जब तक कंपनी का प्रदर्शन नहीं सुधरता।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
CDMO commercial projects
40
+7 projects YoY
Commercial projects increased from 33 to 40 in 9 months, indicating pipeline maturation.
Zanthin capacity (monthly)
500 MT
+300 MT planned
Current run rate 500 MT/month; new capacity of 300 MT/month to be added by Q1 FY27.
Goods in transit (revenue deferred)
₹49 crore
N/A
₹49 crore of sales deferred to Q4 due to DAP incoterm; PBT impact of ₹19 crore.
Atali capex capitalized
₹300 crore
₹150 crore remaining
Total outlay ₹450 crore; ₹300 crore capitalized, balance for phase 2 completion.
What Changed vs Last Quarter
NEW
Zanthin expansion mechanical completion by March 2026
The Zanthin expansion is on track for mechanical completion by end of March 2026, with incremental capacity available from Q1 FY27.
UPDATED
FY26 EBITDA flat to marginal growth
Management expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali delays and API softness.
UPDATED
CDMO revenue guidance for FY26 maintained
Management is confident of meeting the CDMO revenue guidance for FY26, though exceeding the target is now difficult due to project delays.
UPDATED
Atali plant resolution by Q4 FY26
Startup hiccups at Atali are expected to be resolved by end of Q4 FY26, with corrective actions in place.
DROPPED
Zanthin derivative capacity expansion to 9,000 MT by H2 FY26
Brownfield expansion from 5,000 to 9,000 MT per annum will be commissioned in phases during H2 FY26.
NEW RISK
Atali plant stabilization delays
Startup hiccups at Atali have impacted production plans; resolution expected by Q4 but may slip further, delaying revenue ramp-up.
NEW RISK
API business margin pressure and degrowth
API revenue declined YoY due to pricing pressure and slower customer off-take; recovery may take several quarters.
NEW RISK
CDMO revenue concentration on few molecules
80% of CDMO sales come from 7-8 projects; failure of any key project could materially impact revenue.
NEW RISK
China rebate withdrawal benefit may not fully materialize
While China's rebate withdrawal could boost pricing, locked-in contracts may limit near-term realization.
RISK GONE
US tariff policy uncertainty on pharma products
While current tariffs exempt pharma, potential changes under Section 232 could impact API exports; management noted contracts are largely FOB but impact unclear.
RISK GONE
Lumpy CDMO revenue recognition
CDMO revenue is back-end loaded and lumpy due to multi-stage manufacturing; Q1 performance may not be indicative of full-year trajectory.
RISK GONE
Ganesh Polychem joint venture ramp-up risk
GPL plant underwent shutdown for modifications; restart in July may delay contribution to profitability in FY26.
RISK GONE
Capacity utilization drag from new greenfield plant
Atali greenfield plant will have higher opex initially; full utilization may take until end of FY26, pressuring near-term margins.
Fast read
Guidance and risk preview
Management expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali...
Startup hiccups at Atali have impacted production plans; resolution expected by Q4 but may slip further, delaying revenue ramp-up.
View Risks →